Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization

4/20 Early treatment study

Rossignol et al., medRxiv, doi:10.1101/2021.04.19.21255441 (Preprint)
Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization

Source PDF Share Tweet

RCT with 184 outpatients treated with an extended release formulation of nitazoxanide, and 195 controls, showing lower hospitalization and progression to severe disease with treatment. There was one COVID-19 related death in the treatment arm. NCT04486313.

Rossignol et al., 4/20/2021, Double Blind Randomized Controlled Trial, USA, North America, preprint, 8 authors.

risk of death, 206.0% higher, RR 3.06, p = 0.49, treatment 1 of 184 (0.5%), control 0 of 195 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).

risk of hospitalization, 78.8% lower, RR 0.21, p = 0.22, treatment 1 of 184 (0.5%), control 5 of 195 (2.6%).

risk of COVID-19 severe case, 84.9% lower, RR 0.15, p = 0.07, treatment 1 of 184 (0.5%), control 7 of 195 (3.6%).

risk of COVID-19 severe case, 83.9% lower, RR 0.16, p = 0.07, treatment 1 of 112 (0.9%), control 7 of 126 (5.6%), high-risk subgroup.

time to sustained response, 7.5% higher, relative time 1.08, treatment 184, control 195.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 6 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit